| Issue Date | Title | Author(s) |
| 2016 | Assessment of clinical importance of molecular basis of neuroblastoma: can high risk group be categorized as high risk and ultra-high risk? | Demir, B.; Aktas, S.; Altun, Z.; Ercetin, P.; Olgun, N. |
| 2018 | Could Manganese-Superoxide Dismutase be a Biomarker in Neuroblastoma? | Altun, Z.; Aktas, S.; Demir, B.; Serinan, E.; Aktas, T.; Olgun, N. |
| 2018 | Localized Neuroblastoma: The 30 Years Experience of Dokuz Eylul University | Ince, D.; Kizmazoglu, D.; Cecen, E.; Erdem, M.; Altun, Z.; Aktas, S.; Olguner, M. |
| 2021 | Questioning How to Define the Ultra-High-Risk Subgroup of Neuroblastoma Patients | Demir, A. B.; Aktas, S.; Altun, Z.; Ercetin, P.; Aktas, T. C.; Olgun, N. |
| 2018 | Treatment of Children with Intermediate-Risk Neuroblastoma: Dokuz Eylul University Experience | Ince, D.; Erdem, M.; Kizmazoglu, D.; Cecen, E.; Aktas, S.; Altun, Z.; Demiral, A. |
| 2018 | Treatment of Neuroblastoma in Infants Younger than 18 Months: The 30 Years Experience of Dokuz Eylul University | Ince, D.; Kizmazoglu, D.; Erdem, M.; Aktas, S.; Cecen, E.; Altun, Z.; Demiral, A. |
